8,325
Views
26
CrossRef citations to date
0
Altmetric
Coronaviruses

Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma

, , , , , , , , , , & show all
Pages 425-428 | Received 23 Dec 2021, Accepted 05 Jan 2022, Published online: 28 Jan 2022

References

  • WHO. WHO Coronavirus (COVID-19) Dashboard. 2021. Available from: https://covid19.who.int/.
  • Tregoning JS, Flight KE, Higham SL, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626–636. DOI:10.1038/s41577-021-00592-1.
  • WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. 2021. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
  • CDC. Science brief: Omicron (B.1.1.529) variant. 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html.
  • Wu F, Liu M, Wang A, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, china. JAMA Intern Med. 2020;180(10):1356–1362. DOI:10.1001/jamainternmed.2020.4616.
  • Cao YR, Wang J, Jian F, et al. B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. bioRxiv. 2021. DOI:10.1101/2021.12.07.470392
  • Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021. DOI:10.1101/2021.12.08.21267417.
  • Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization properties of the SARS-CoV-2 Omicron variant. medRxiv. 2021. DOI: 10.1101/2021.12.12.21267646
  • Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv. 2021. DOI:10.1101/2021.12.07.21267432
  • Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. 2022;11(1):1–5.
  • Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 COVID vaccine over 6 months. N Engl J Med. 2021;385:e84.
  • Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:10316.
  • Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2021. DOI:10.1080/22221751.2021.2022440
  • Uriu K, Kimura I, Shirakawa K, et al. Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum. N Engl J Med. 2021;385:2397–2399. DOI:10.1056/NEJMc2114706.